Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021
Open Access
- 1 July 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e469-e476
Abstract
Background: Belief that vaccination is not needed for individuals with prior infection contributes to coronavirus disease 2019 (COVID-19) vaccine hesitancy. Among individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before vaccines became available, we determined whether vaccinated individuals had reduced odds of reinfection. Methods: We conducted a case-control study among adult New York City residents who tested positive for SARS-CoV-2 infection in 2020 and had not died or tested positive again >90 days after an initial positive test as of 1 July 2021. Case patients with reinfection during July 2021–November 2021 and controls with no reinfection were matched (1:3) on age, sex, timing of initial positive test in 2020, and neighborhood poverty level. Matched odds ratios (mORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: Of 349 827 eligible adults, 2583 were reinfected during July 2021–November 2021. Of 2401 with complete matching criteria data, 1102 (45.9%) were known to be symptomatic for COVID-19-like illness, and 96 (4.0%) were hospitalized. Unvaccinated individuals, compared with individuals fully vaccinated within the prior 90 days, had elevated odds of reinfection (mOR, 3.21; 95% CI, 2.70 to 3.82), of symptomatic reinfection (mOR, 2.97; 95% CI, 2.31 to 3.83), and of reinfection with hospitalization (mOR, 2.09; 95% CI, .91 to 4.79). Conclusions: Vaccination reduced odds of reinfections when the Delta variant predominated. Further studies should assess risk of severe outcomes among reinfected persons as new variants emerge, infection- and vaccine-induced immunity wanes, and booster doses are administered.Keywords
All Related Versions
Funding Information
- CDC
This publication has 16 references indexed in Scilit:
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantNew England Journal of Medicine, 2021
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesNew England Journal of Medicine, 2021
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Predictors of intention to vaccinate against COVID-19: Results of a nationwide surveyVaccine, 2021
- COVID-19 Outbreak — New York City, February 29–June 1, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patientsJournal of Infection, 2020
- Magnitude and Kinetics of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease SeverityClinical Infectious Diseases, 2020